Spyre Therapeutics (SYRE) is down -7.4%, or -$2.43 to $30.33.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
- Spyre Therapeutics initiated with an Outperform at Mizuho
- Spyre Therapeutics initiated with a Buy at Citi
- Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls